Chimeric antigen receptor (CAR) modified T cells have emerged as powerful tools for controlling leukemias. We recently showed that anti-CD123 CAR-expressing cytokine-induced killer T cell treatment is an effective immunotherapeutic approach to eradicate Acute Myeloid Leukemia (AML) cells. Here, we discuss how this genetically modified cell-based strategy could be relevant to the field of AML therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106165 | PMC |
| http://dx.doi.org/10.4161/onci.28835 | DOI Listing |
Publication Analysis
Top Keywords
chimeric antigen
8
cd123 aml
4
aml targeting
4
targeting chimeric
4
antigen receptors
4
receptors novel
4
novel magic
4
magic bullet
4
bullet aml
4
aml therapeutics?
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!